- $669.93m
- $346.09m
Brief: Aura Biosciences - May Offer Securities Up To $500 Million Aggregate
Brief: Aura Biosciences Reports Second Quarter 2026 Financial Results And Recent Business Highlights
U.S. RESEARCH ROUNDUP-Aecom, Humana, Mosaic
Aura Biosciences Q1 net loss widens on higher R&D costs
Brief: Aura Biosciences Q1 Operating Expenses USD 34.866 Million
Brief: Aura Biosciences Announces Pricing Of $260 Million Public Offering Of Common Stock And Pre-Funded Warrants
Aura Biosciences 2025 net loss widens as R&D costs rise
Brief: Aura Biosciences FY Operating Expenses USD 112.791 Million
Aura Biosciences Q3 net loss widens as R&D costs rise
Brief: Aura Biosciences Q3 Operating Expenses USD 27.906 Million
Aura Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Aura Biosciences Inc expected to post a loss of 46 cents a share - Earnings Preview
Aura Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary
Aura Biosciences Inc expected to post a loss of 49 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Xponential Fitness, Phillips 66, Amazon.com
U.S. STOCKS ON THE MOVE-Intuitive Surgical, Boeing, Abbott
Brief: Aura Biosciences Announces Proposed Public Offering Of Common Stock And Warrants
Brief: Aura Biosciences Q1 Operating Expenses USD 29.035 Million
Aura Biosciences Inc expected to post a loss of 49 cents a share - Earnings Preview